Marchenko K. Raising up pharmacotherapeutic efficacy of lovastatin under hyperlipidemiae in patients with ischemic heart disease by tecome and tri-vi plus.

The dissertation deals with investigating the effect of hypolipidemic therapy on the clinical course and biochemical indicators of blood lipids in patients with ischemic heart disease. For the first time it was been carried out the comparison of lovastatin efficacy and safety on the background of the basic antianginal therapy, with polyunsaturated fatty acids n-3 drug - tecome (epadole) under dyslipidemiae. It was been shown that the optimal variant was the treatment by three drugs with different action mechanisms - lovastatin (dosage 20 mg per 24 h) and tecome (2,0 g per 24 h) and tri-vi plus (1 tablet per 24 h) during 4 weeks. The purely tecome therapy was accompanied by the lesser hypolipidemic effect, the increase of polyunsaturated fatty acids of blood, but by the tendency to aggravating of lipoperoxidation as well. The two drugs therapy (lоvastatin and tecome) on the background of the hypolipidemic effect was less favorable because of the increase of lipid peroxidation. The individual risk factors in patients (female gender, smoking, excessive body mass) decreased the efficacy of hypolipemic treatment and aggravated peroxidation status.